Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OpenProtein.AI is a biotechnology company specializing in AI-driven protein engineering and design. The company provides a cloud-based platform that utilizes generative protein language models, such as PoET, to predict and optimize protein properties including binding affinity, stability, and expressibility. By integrating large-scale evolutionary data with user-provided experimental results, the platform enables the rapid design of novel variants for antibodies, enzymes, and other therapeutic proteins. OpenProtein.AI aims to streamline the drug discovery process by reducing the number of experimental iterations required to achieve target product profiles. The company is headquartered in Hillsborough, North Carolina, and maintains a research presence in Singapore.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Open Protein.